Cargando…
The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model
Treatment with the second and third generation BCR-ABL1 tyrosine kinase inhibitors (TKIs) increases cardiovascular risk in chronic myeloid leukemia (CML) patients. We investigated the vascular adverse effects of three generations of TKIs in a translational model for atherosclerosis, the APOE*3Leiden...
Autores principales: | Pouwer, Marianne G., Pieterman, Elsbet J., Verschuren, Lars, Caspers, Martien P. M., Kluft, Cornelis, Garcia, Ricardo A., Aman, Jurjan, Jukema, J. Wouter, Princen, Hans M. G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005845/ https://www.ncbi.nlm.nih.gov/pubmed/29946549 http://dx.doi.org/10.3389/fcvm.2018.00055 |
Ejemplares similares
-
Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment
por: Oaxaca, Derrick M., et al.
Publicado: (2016) -
Ponatinib Is a Pan-BCR-ABL Kinase Inhibitor: MD Simulations and SIE Study
por: Tanneeru, Karunakar, et al.
Publicado: (2013) -
Dose Effects of Ammonium Perfluorooctanoate on Lipoprotein Metabolism in APOE*3-Leiden.CETP Mice
por: Pouwer, Marianne G, et al.
Publicado: (2019) -
Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines
por: Lu, Liu, et al.
Publicado: (2018) -
Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib
por: Dessilly, Géraldine, et al.
Publicado: (2016)